

Capstone Therapeutics Corp.  
Form 8-K  
August 23, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report: August 23, 2011 (Date of earliest event reported)

CAPSTONE THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

|   |                                       |   |
|---|---------------------------------------|---|
| Delaware<br>(State or other jurisdiction of<br>incorporation) | 000-21214<br>(Commission File Number) | 86-0585310<br>(I.R.S. Employer<br>Identification No.) |
|---|---------------------------------------|---|

|   |                     |
|---|---------------------|
| 1275 West Washington Street, Suite 101, Tempe,<br>Arizona<br>(Address of principal executive offices) | 85281<br>(Zip Code) |
|---|---------------------|

Registrant's telephone number, including area code:  
(602) 286-5520

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Section 7 – Regulation FD

Item 7.01. Regulation FD Disclosure.

The information in this Current Report, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language contained in such filing.

On August 23, 2011, Capstone Therapeutics Corp. issued a press release announcing a quarterly Company update via teleconference and webcast. The accompanying slides can be viewed by logging onto the Investors section of the Company’s website, [www.capstonethx.com](http://www.capstonethx.com). A copy of the press release is attached as Exhibit 99.1 and a copy of the presentation entitled “Capstone Therapeutics Quarterly Company Update, August 23, 2011” is attached as Exhibit 99.2 and are incorporated by reference herein.

Section 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

| Exhibit No. | Description                               |
|-------------|---|
| 99.1        | Press Release dated August 23, 2011       |
| 99.2        | Quarterly Company Update, August 23, 2011 |

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 23, 2011

CAPSTONE THERAPEUTICS  
CORP.

/s/ John M. Holliman, III  
John M. Holliman, III  
Executive Chairman